With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Learn More » Beyond Mounjaro and Zepbound, I'd encourage investors to take a serious look at Lilly's oncology business. Below ...

president of Lilly Oncology. The agreement includes an upfront payment and subsequent payments upon achieving certain regulatory and sales milestones. As part of the deal, Scorpion will spin out a ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) ...

For more information on Lilly's Oncology pipeline click here. LY4170156 was designed to target FRα across expression levels with an improved therapeutic index. LY4170156 is composed of a Fc ...

I know we're starting a little bit late. My name is Jake Van Naarden. I lead the oncology unit here at Lilly, which, in the case of oncology, actually spans our discovery efforts all the way ...

"We are fortunate to have entered into an agreement with Lilly given its global development capability, oncology expertise, and the radiopharmaceutical experience and capabilities Lilly is ...

5, 2024. Jacob Van Naarden, executive vice president and president, Lilly Oncology, will participate in a fireside chat at 7:45 a.m. Eastern time. A live audio webcast will be available on the ...

For two decades, Oncology on Canvas® has provided people in the cancer ... The program, a partnership between Lilly, the National Coalition for Cancer Survivorship and the Cancer Support Community, ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...